We are live on ! Find out more
BLACR

Bellevue Life Sciences Acquisition Corp. Rights
BLACR

Delisted

BLACR was delisted on the 14th of February, 2025.

Back to rankings

28 hedge funds and large institutions have $681K invested in Bellevue Life Sciences Acquisition Corp. Rights in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more capital invested

Capital invested by funds: $550K → $681K (+$131K)

0% more funds holding

Funds holding: 28 → 28 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

71% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 7

Holders
28
Holders Change
–
Holders Change %
0%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
7
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
+$56K
2
Walleye Trading
Walleye Trading
New York
+$17.8K
3
Citadel Advisors
Citadel Advisors
Florida
+$13

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$17.8K
2
SCM
Shaolin Capital Management
Florida
-$17.4K
3
SIA
Schechter Investment Advisors
Michigan
-$3.76K
4
BI
Bulldog Investors
New Jersey
-$1.61K
5
PC
Periscope Capital
Ontario, Canada
-$389
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$100K – – –
PC
2
Periscope Capital
Ontario, Canada
$65.2K -$389 -3,100 -0.6%
HCI
3
Harraden Circle Investments
New York
$58.3K +$65.8K +524,343 New
Toronto Dominion Bank
4
Toronto Dominion Bank
Ontario, Canada
$48.7K +$56K +446,448 New
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$46.8K – – –
BFM
6
Boothbay Fund Management
New York
$41.8K – – –
ASM
7
ATW SPAC Management
New York
$40.4K – – –
JP Morgan Chase
8
JP Morgan Chase
New York
$36K – – –
SCM
9
Saba Capital Management
New York
$33.6K – – –
Walleye Trading
10
Walleye Trading
New York
$30.7K +$17.8K +141,858 +150%
RCM
11
Rivernorth Capital Management
Florida
$28.6K – – –
CS
12
Clear Street
New York
$24.2K – – –
HCM
13
Heights Capital Management
California
$20.3K – – –
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$18K – – –
SCM
15
Shaolin Capital Management
Florida
$16.3K -$17.4K -138,867 -53%
WAM
16
Wolverine Asset Management
Illinois
$15.8K – – –
AA
17
AQR Arbitrage
Connecticut
$12.8K -$185 -1,472 -1%
CC
18
Centiva Capital
New York
$12K – – –
MTCM
19
Mint Tower Capital Management
Netherlands
$10K – – –
SIA
20
SkyView Investment Advisors
New Jersey
$4K – – –
GF
21
Gabelli Funds
New York
$3.52K – – –
Walleye Capital
22
Walleye Capital
New York
$3.42K -$17.8K -141,858 -84%
Citadel Advisors
23
Citadel Advisors
Florida
$2.93K +$13 +100 +0.4%
GCIA
24
Gabelli & Co Investment Advisers
New York
$2.7K – – –
FTUS
25
Flow Traders U.S.
New York
$2K -$76 -610 -4%
1
2

BLACR Hedge Fund Activity: Q4 2024 in Review

28 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q4 2024, worth a combined $681K — up 24% from $550K a quarter earlier.

Fund positioning in BLACR was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 7 trimmed.

The largest buyer was Toronto Dominion Bank, opening a new position worth an estimated $56K. The largest seller was Walleye Capital, cutting an estimated $17.8K.

  • 28 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $681K of Bellevue Life Sciences Acquisition Corp. Rights stock for Q4 2024, up 24% quarter-over-quarter.
  • 2 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q4 2024 and 2 closed out, a net change of 0 holders.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q4 2024 was Toronto Dominion Bank, an estimated $56K added.
  • The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q4 2024 was Walleye Capital, an estimated $17.8K sold.

Based on aggregated 13F filings for Q4 2024.